Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Xenon Pharmaceuticals stock
Learn how to easily invest in Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 123 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Xenon Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – XENE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Xenon Pharmaceuticals stock price (NASDAQ: XENE)Use our graph to track the performance of XENE stocks over time.
Xenon Pharmaceuticals shares at a glance
|Latest market close||$26.00|
|52-week range||$13.98 - $36.42|
|50-day moving average||$29.46|
|200-day moving average||$22.35|
|Wall St. target price||$45.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.55|
Buy Xenon Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Xenon Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Xenon Pharmaceuticals price performance over time
|1 week (2022-01-14)||-18.65%|
|1 month (2021-12-21)||N/A|
|3 months (2021-10-25)||-15.39%|
|6 months (2021-07-23)||42.08%|
|1 year (2021-01-25)||62.81%|
|2 years (2020-01-24)||67.74%|
|3 years (2019-01-24)||232.91%|
|5 years (2017-01-24)||222.98%|
Xenon Pharmaceuticals financials
|Revenue TTM||$19.9 million|
|Gross profit TTM||$-18,357,000|
|Return on assets TTM||-18.09%|
|Return on equity TTM||-30.46%|
|Market capitalisation||$1.7 billion|
TTM: trailing 12 months
Xenon Pharmaceuticals share dividends
We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.
Xenon Pharmaceuticals share price volatility
Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $13.9827 up to $36.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.8956. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Xenon Pharmaceuticals overview
Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1. 6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc.
Xenon Pharmaceuticals in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Markets are expected to remain on edge as the Fed meets in the week ahead
Netflix quietly admits streaming competition is eating into growth
Frequently asked questionsWhat percentage of Xenon Pharmaceuticals is owned by insiders or institutions?
Currently 2.274% of Xenon Pharmaceuticals shares are held by insiders and 70.513% by institutions. How many people work for Xenon Pharmaceuticals?
Latest data suggests 123 work at Xenon Pharmaceuticals. When does the fiscal year end for Xenon Pharmaceuticals?
Xenon Pharmaceuticals's fiscal year ends in December. Where is Xenon Pharmaceuticals based?
Xenon Pharmaceuticals's address is: 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 What is Xenon Pharmaceuticals's ISIN number?
Xenon Pharmaceuticals's international securities identification number is: CA98420N1050 What is Xenon Pharmaceuticals's CUSIP number?
Xenon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98420N105
More guides on Finder
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert